

PANKAJ SRIVASTAVA

Research Associate

Dept of Microbiology and Immunology, School of Medicine, UNC-Chapel Hill

Email: srivaspa@unc.edu

EDUCATION

PhD in Biotechnology (Molecular Parasitology):

Infectious Disease Research Laboratory, Institute of Medical Sciences, Banaras Hindu University,
Varanasi, India. 2012

Masters in Biotechnology:

VBS Purvanchal University, Jaunpur, UP, India.

Bachelor of Science: Zoology, Botany and Chemistry

Lucknow Christian College, Lucknow University, UP, India

RESEARCH EXPERIENCE

- **July 2022 to till date** Research Associate, Cameron and Arnold Laboratory, Dept of Microbiology and Immunology, UNC Chapel Hill.
- **Sept 2021 to May 2022** Postdoctoral Research Associate, Liu Lab, Div. of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, UNC Chapel Hill.
- **Jan 2020 to Sept 2021** Research Instructor, Zhao Lab, Dept of Biochemistry and Molecular Genetics, Univ of Colorado, Anschutz Medical Campus, Denver-CO on the project entitled "Coupling between Transcription and Splicing mediated by Small Nuclear Ribonucleoproteins in Yeast".

- **June 2016 to December 2019** Staff Scientist, Nihalani Lab, division of Nephrology, Medical University of South Carolina, SC, USA.
- **Sept. 2011 to May 2016** Postdoctoral Fellow, Bastia Lab, dept. of Biochemistry and Molecular Biology, Medical University of South Carolina, SC, USA.
- **2006-2011** Ph.D. thesis research entitled “Indian Visceral Leishmaniasis - Studies on Molecular Approaches to Characterization of Clinical Isolates and Diagnosis”. Thesis Advisor: Prof. Shyam Sundar
- **Jan–April 2004** M.Sc. thesis on the topic “Y chromosome polymorphism in Rajput and Brahmin population groups of Himachal Pradesh” National Centre of Applied Human Genetics, School of Life Sciences, Jawaharlal Nehru University, New Delhi, India.
- **May, 2003** Summer trainee at National JALMA (Japanese Leprosy Mission for Asia) Institute of Leprosy and other Mycobacterial Disease, Agra, UP, India.

PUBLICATIONS:

During Postdoc/Staff Scientist:

1. D Bastia, **Pankaj Srivastava***, S Zaman*, M Chaudhary*, B K Mohanty*, J Bacal, L D. Langston, P Pasero, M. E. O’ Donnell. Phosphorylation of CMG helicase and Tof1 is required for programmed fork arrest. **(PNAS), 2016. Impact Factor 13.**
2. S Zaman*, M Chaudhary*, J Jiang*, **Pankaj Srivastava**, B Mohanty, C Danielson, S Humphrey, S. M. Jazwinski, D Bastia. Mechanism of regulation of intrachromatid recombination and long range chromosome interactions In *Saccharomyces cerevisiae*. **(Molecular and Cellular Biology) 2016.** Impact Factor 4.2
3. Chinthapatla, R., Sotoudegan, M., **Srivastava, P.**, Anderson, T., Moustafa, I.M., Passow, K.T.,

Kennelly, S.A., Moorthy, R., Dulin, D., Feng, J., Harki, D., Kirchdoerfer, R., Cameron, C.E., Arnold, J.J., (Dec 2022). Interfering with nucleotide excision by the coronavirus 3'-to-5' exoribonuclease.

InPress; Nucleic Acid Research. Impact Factor 19.2.

4. A Sagar, E Arif, A Solanki, **Pankaj Srivastava**, S Kwon, Ashish, D Nihalani. Targeting Neph1 and ZO-1 protein-protein interaction in podocytes prevents podocyte injury and preserves glomerular filtration function. (**Nature-Scientific Reports**; 2017. Impact Factor 4.4).
5. **Pankaj Srivastava***, A Solanki*, E Arif, S Kwon, B J Wolf, M G Janech, M N. Budisavljevic, D Nihalani. Development of a novel cell-based assay to diagnose recurrent Focal and Segmental Glomerulosclerosis. **Kidney International**; 2018. **Impact Factor: 19.**
6. D Nihalani, A Solanki, E Arif, **Pankaj Srivastava**, B Rahman, X Zuo, Y Dang, H Alsudan, S Ghoshroy, M Sampson, J H Lipschutz. Disruption of the exocyst induces podocyte loss and dysfunction. **J of Biological Chemistry**-2019. Impact Factor: 5.5
7. A Solanki, **Pankaj Srivastava** et al. The Use of High-Throughput Transcriptomics to Identify Pathways with Therapeutic Significance in Podocytes. **International J of Molecular Sciences**-2020; Impact Factor-6.2
8. E Arif, A Solanki, **Pankaj Srivastava**, B R Tash, L B Holzman, M G Janech, R Martin, H-J Knölker, W R Fitzgibbon, P Deng, M N Budisavljevic, Wing Syn, C Wang, SH Kwon, Deepak Nihalani. The motor protein Myo1c regulates transforming growth factor- β -signaling and fibrosis in podocytes. **Kidney International**; 2019; **Impact Factor: 19.**
9. E Arif, A Solanki, **Pankaj Srivastava**, B Rahman, J Megyesi, M Janech, S H Kwon, J Collier, R G Schnellmann, D Nihalani: Mitochondrial biogenesis induced by the β_2 -adrenergic receptor agonist formoterol accelerates podocyte recovery from injury. **Kidney International**; 2019; **Impact Factor: 19.**

10.A Solanki, E Widmeier, E Arif, A Daga, M Helmstadter, **Pankaj Srivastava**, S Kwon, S Shril, C Bergmann, Tobias Huber, Friedhelm Hildebrandt, Deepak Nihalani. Mutations in KIRREL1 a slit diaphragm component cause steroid-resistant nephrotic syndrome. **Kidney International**-2019.

Impact Factor: 19.

11.A Solanki, E Arif, **Pankaj Srivastava** et al. Phosphorylation of slit diaphragm proteins NEPHRIN and NEPH1 upon binding of HGF promotes podocyte repair. **J of Biological Chemistry, Sept 2021;**

Impact factor- 5.5

From PhD:

12.**Pankaj Srivastava**, VK Prajapati, GVD Auwera, JC Dujardin, S Sundar. Detection of *Leptomonas sp.* parasites in clinical isolates of Kala-azar patients from India, (**Infection, Genetics and Evolution**: 2010. Impact Factor 3.3

13.A Picado, S Singh, S Rijal, S Sundar, B Ostyn, F Chappuis, S Uranw, K Gidwani, B Khanal, M Rai, I Paudel, M Lal, P Das, R Kumar, **Pankaj Srivastava**, JC Dujardin, V Vanlerberghe, EW Andersen, CR Davies, M Boelaert. Long lasting insecticidal nets for the prevention of *Leishmania donovani* infection in India and Nepal: paired cluster randomised trial (**British Medical Journal**, 2010. **Impact Factor 93.3**).

14.**Pankaj Srivastava**, T Singh, S Sundar. Genetic heterogeneity in *Leishmania donovani* clinical isolates from India. **Journal of Clinical Microbiology**, 2011. Impact Factor 6.0.

15.**Pankaj Srivastava**, S Mehrotra, P Tiwari, J Chakravarty, S Sundar. Diagnosis of Indian Visceral Leishmaniasis by Nucleic Acid Detection using PCR (**Plos One**: 2011 Impact Factor 3.2

16.**Pankaj Srivastava**, VK Prajapati, M Rai, S Sundar. Unusual Case of Resistance to Amphotericin B in Visceral Leishmaniasis in a Region in India Where Leishmaniasis is not Endemic. **Journal of Clinical Microbiology**, 2011. Impact Factor 6.0

17.S Mohan, **Pankaj Srivastava**, SN Maheshwari S Sundar, R Prakash. Nano Structured Nickel Oxide based DNA Biosensor for Detection of Visceral Leishmaniasis (**Analyst**, 2011; Impact Factor 5.3).

18.**Pankaj Srivastava**, A Dayama, S Mehrotra, S Sundar. Diagnosis of Visceral Leishmaniasis-Review **Transactions of the Royal Society of Tropical Medicine and Hygiene**: 2011. Impact factor: 2.8

19.**Pankaj Srivastava**, K Gidwani, A Picado, GVD Auwera, P Tiwary, B Ostyn, JC Dujardin, M Boelaert, S Sundar. Molecular and serological markers of *Leishmania donovani* infection in healthy individuals from endemic areas of Bihar, India. **Tropical Medicine and International Health**, 2013. Impact Factor 4.0

20.NCBI Gen Bank Submissions:

A: Accession No- FJ226475, HQ159842 and GU143558

B: GEO Data Sets (RNA-Seq): Accession: GSE117669 and ID: 200117669

***Number of citations of all papers: 930+**

Invited Talks & Presentations

A. Oral presentation in Nephrology Young Investigators' Forum (Southern Society for Clinical Investigation) 2017 meeting held in New Orleans (Feb, 2017). **Title:** A Novel Role for the Phosphatase SHP2 in Regulating Glomerular Filtration Function.

B. Oral presentation in American Society of Nephrology conference. Nov 2017. **Title:** Diagnosing recurrent FSGS using a novel cell-based assay.

C. Presented my research work in Research and Methods seminar series, dept. of Biochemistry and Molecular Biology, Medical University of South Carolina, SC, USA on 24th March, 2015. **Title:** Phosphorylation of CMG helicase and Tof1 is required for programmed fork arrest.

Expertise: Molecular Biology, Protein and nucleic acid biochemistry, Cell Biology